FDA Eyes Pill Pipelines to Sniff Out Fake Meds
Published Date: 5/1/2025
Notice
Summary
The FDA is asking for approval to collect info about how medicines move through the supply chain to keep drugs safe and real. This affects drug makers, distributors, and pharmacies who must share certain details to track medicines better. The goal? Make sure your meds are legit without causing big delays or extra costs.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Supply-Chain Data Sharing Duty
If you run or work for a drug maker, distributor, or pharmacy, you must share certain details about how medicines move through the supply chain so drugs can be tracked better. The FDA is seeking approval to collect that information under the Paperwork Reduction Act.
Stronger Assurance Medicines Are Legit
You will benefit from better tracking of how medicines move through the supply chain because the FDA is collecting information to keep drugs safe and real. The agency says the goal is to ensure your medicines are legitimate while not causing big delays or extra costs.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in